The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“[ 108] [109] Overall, the NAS and SAF score share many similarities, but they are not interchangeable, and both the NASH CRN and SAF score show improved interobserver variability and has been validated clinically.”
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationBCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319 · cited 1×
“When HCC is diagnosed at an early stage, there are existing acceptable and curative therapies, for example, surgical resection, local ablation, or liver transplantation [291].”
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 1×
“A person living with MAFLD plays a vital role in their disease management as the cornerstone of treatment is adherence to a healthy diet and being physically active [24, 156, 251].”
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052 · cited 2×
“Based on cost-effectiveness analyses, when the incidence of HCC is > 1 or 2%/year, it is cost-effective to perform HCC screening/surveillance [295–297].”
InfluentialA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“…in patients with MASH, semaglutide at a dose of 0.4 mg daily given subcutaneously for 72 weeks achieved MASH resolution with no worsening of fibrosis in 59% of patients, compared with 17% in the placebo group, though differences in fibrosis improvement did not reach statistical significance [241].”
InfluentialA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“The beneficial effects of pioglitazone on hepatic histology have been reported in patients with steatohepatitis, with and without T2DM [206, 207].”
Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
A new system for grading recommendations in evidence based guidelines
Harbour, R., & Miller, J. (2001) · BMJ · doi:10.1136/bmj.323.7308.334 · Cited by 1,637 · cited 1×
“Of these, 9% had Table 1 Evidence grade used for the APASL Clinical Practice Guidelines on MAFLD (adapted from the GRADE system) [3] Grading of evidence Notes Symbol High quality Further research is very unlikely to change our confidence in the estimate effect A Moderate quality Further research is…”
Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275 · cited 1×
“Based on a meta-analysis of biopsy-based studies, optimal cut-offs of 248, 268 and 280 dB/m were reported for histological mild, moderate and severe steatosis respectively, achieving area under the curves of 0.82–0.89 [93].”
InfluentialSelf-citationEASL Clinical Practice Guidelines on nutrition in chronic liver disease
Merli, M., Berzigotti, A., Zelber-Sagi, S., Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., & Parés, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.024 · Cited by 1,130
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Self-citationEisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., De Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.08.013 · Cited by 985 · cited 1×
“Within the Asian context, the ethnicity-adjusted BMI risk thresholds for obesity should be used and should also take into account metabolic comorbidity risk [198].”
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925
Self-citationRegulation of glucose metabolism from a liver-centric perspective
Han, H.-S., Kang, G., Kim, J. S., Choi, B. H., & Koo, S.-H. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.122 · Cited by 835
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801 · cited 1×
“Lanifibranor (a pan-PPAR agonist) [246] and fibroblast growth factor-21 analogues (e.g., efruxifermin and pego-zafermin) have also shown promising results in early-stage clinical trials, while phase 3 studies are underway [247, 248].”
Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease
Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795 · cited 3×
“To resolve this issue, more sensitive and reliable biomarkers of risk, or scoring systems for surveillance that improve cost-effectiveness is required [299–301].”
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Self-citationKuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · cited 2×
“Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been widely used for the treatment of T2DM and cardiovascular disease, with some evidence of benefit for MAFLD [209, 210].”
Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622 · cited 1×
“Randomized controlled studies with bariatric surgery have demonstrated up to 3.6-fold higher efficacy in the resolution of biopsy-proven steatohepatitis without worsening of liver fibrosis compared to standard medical therapy [201]; these benefits can be sustained for up to 5 years [202].”
InfluentialKorenblat, K. M., Fabbrini, E., Mohammed, B. S., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.075 · Cited by 592
Bryazka, D., Reitsma, M. B., Griswold, M. G., Abate, K. H., Abbafati, C., Abbasi-Kangevari, M., Abbasi-Kangevari, Z., Abdoli, A., Abdollahi, M., Abdullah, A. Y. M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00847-9 · Cited by 582
Self-citationPeiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522 · cited 1×
“Lanifibranor (a pan-PPAR agonist) [246] and fibroblast growth factor-21 analogues (e.g., efruxifermin and pego-zafermin) have also shown promising results in early-stage clinical trials, while phase 3 studies are underway [247, 248].”
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review
Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.023 · Cited by 509 · cited 1×
“A meta-analysis showed that resistance exercise improves MAFLD with less energy consumption [190].”
Self-citationSarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440
Self-citationHarrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023) · Nature Medicine · doi:10.1038/s41591-023-02603-1 · Cited by 435 · cited 1×
“In the accompanying MAESTRO-NAFLD-1 study based entirely on noninvasive tests, resmetirom again demonstrated superiority in reducing hepatic fat, liver stiffness, serum LDL-cholesterol, apolipoprotein B and triglycerides [239].”
Boursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.023 · Cited by 400
Lipid metabolism during endurance exercise
Horowitz, J. F., & Klein, S. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.2.558s · Cited by 397
Hong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385 · cited 1×
“The risk of MAFLD increases in the presence of sarcopenia, and sarcopenia is associated with significant fibrosis [36–38].”
Self-citationEn Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380
Self-citationAminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Association of histologic disease activity with progression of nonalcoholic fatty liver disease
Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12565 · Cited by 372 · cited 1×
“However, a recent study has shown that current reporting systems remain suboptimal for end-point determination in clinical trials [110, 111].”
Lee, Y., Doumouras, A. G., Yu, J., Brar, K., Banfield, L., Gmora, S., Anvari, M., & Hong, D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.10.017 · Cited by 371 · cited 2×
“Liver fibrosis can progress in a subset of these patients and monitoring is recommended [200].”
Epidemiology and risk-stratification of NAFLD-associated HCC
Ioannou, G. N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.012 · Cited by 361
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360
Berzigotti, A., Albillos, A., Villanueva, C., Genescá, J., Ardevol, A., Augustín, S., Calleja, J. L., Bañares, R., García‐Pagán, J. C., Mesonero, F., et al. (2017) · Hepatology · doi:10.1002/hep.28992 · Cited by 334 · cited 1×
“Additionally, 5–10% weight loss via lifestyle interventions has been reported to improve portal hypertension in patients with cirrhosis [354].”
Effect of aerobic exercise training dose on liver fat and visceral adiposity
Keating, S. E., Hackett, D. A., Parker, H. M., O’Connor, H. T., Gerofi, J. A., Sainsbury, A., Baker, M. K., Chuter, V. H., Caterson, I. D., George, J., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.022 · Cited by 313 · cited 1×
“While intensity-dependent benefits are not apparent for hepatic steatosis [180–182], emerging evidence demonstrates that high-intensity interval training (HIIT) involving one or more bursts of high-intensity exercise interspersed with lower-intensity recovery periods is equally effective under the…”
Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290 · cited 2×
“However, metformin improves insulin resistance [219, 221, 222] and reduces the risk of HCC in patients with MAFLD, although available studies have not been prospective or randomized [223, 224].”
Stine, J. G., Munaganuru, N., Barnard, A., Wang, J. L., Kaulback, K., Argo, C. K., Singh, S., Fowler, K. J., Sirlin, C. B., & Loomba, R. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.061 · Cited by 283
Beleigoli, A. M., Andrade, A. Q., Cançado, A. G., Paulo, M. N., Diniz, M. D. F. H., & Ribeiro, A. L. (2019) · Journal of Medical Internet Research · doi:10.2196/jmir.9609 · Cited by 278 · cited 1×
“For the initiation and maintenance of lifestyle change in patients with MAFLD and for patient empowerment, there is evidence to support the use of digital technology for providing their screening results together with advice on lifestyle changes [255, 256].”
Vilar‐Gomez, E., Nephew, L. D., Vuppalanchi, R., Gawrieh, S., Mladenovic, A., Pike, F., Samala, N., & Chalasani, N. (2022) · Hepatology · doi:10.1002/hep.32207 · Cited by 277 · cited 1×
“A diet comprising added sugar (fructose, high-fructose corn syrup, and sucrose), such as sugar-sweetened beverages, excess saturated fat (for instance, palm oil), as well as ultra-processed foods (UPF), should be avoided [151, 153].”
Zhang, H.-J., He, J., Pan, L.-L., Ma, Z.-M., Han, C.-K., Chen, C.-S., Chen, Z., Han, H.-W., Chen, S., Sun, Q., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3202 · Cited by 276
Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00272-8 · Cited by 276
Increased perioperative mortality following bariatric surgery among patients with cirrhosis
Mosko, J. D., & Nguyen, G. C. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.07.007 · Cited by 266
Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA · doi:10.1001/jama.2024.1447 · Cited by 250 · cited 1×
“The most accurate non-invasive method to quantify liver fibrosis is MR elastography [83], but this has limited accessibility and requires additional technical hardware beyond a standard MR scan and is not recommended as a first-line approach for risk stratification in a patient with MAFLD [84].”
Self-citationHolmer, M., Lindqvist, C., Petersson, S., Moshtaghi-Svensson, J., Tillander, V., Brismar, T. B., Hagström, H., & Stål, P. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100256 · Cited by 224 · cited 1×
“Ketogenic diets reduce body weight and liver steatosis but not fibrosis as suggested by previous small randomized-controlled trials [165, 166].”
Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., Bedossa, P., Geier, A., Francque, S., Allison, M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00017-1 · Cited by 224
Orci, L. A., Sanduzzi-Zamparelli, M., Caballol, B., Sapena, V., Colucci, N., Torres, F., Bruix, J., Reig, M., & Toso, C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.002 · Cited by 218 · cited 1×
“A systematic review showed that among 470,404 MAFLD patients, the incidence rate of HCC was 0.03/100 person-years, and 3.78/100 person-years in the pre-cirrhotic and cirrhotic stages, respectively [61].”
InfluentialMózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00141-3 · Cited by 214 · cited 2×
“The abovementioned FIB-4 and LSM combination are independent predictors of liver-related events [81, 102], and on their own had a similar predictability as histolog-ically-assessed liver fibrosis [65].”
Self-citationChoi, H. S. J., Brouwer, W. P., Zanjir, W. M. R., de Man, R. A., Feld, J. J., Hansen, B. E., Janssen, H. L. A., & Patel, K. (2020) · Hepatology · doi:10.1002/hep.30857 · Cited by 211
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211 · cited 1×
“This class of drugs reduces appetite and slows gastric emptying, resulting in weight loss of 5–15% [240].”
Haigh, L., Kirk, C., El Gendy, K., Gallacher, J., Errington, L., Mathers, J. C., & Anstee, Q. M. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.06.037 · Cited by 209
Houghton, D., Thoma, C., Hallsworth, K., Cassidy, S., Hardy, T., Burt, A. D., Tiniakos, D., Hollingsworth, K. G., Taylor, R., Day, C. P., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.031 · Cited by 209
Boursier, J., Hagström, H., Ekstedt, M., Moreau, C., Bonacci, M., Cure, S., Ampuero, J., Nasr, P., Tallab, L., Canivet, C. M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.031 · Cited by 206 · cited 2×
“Subjects with an indeterminate FIB-4 and a subsequent LSM of 8 kPa can be managed in primary care and have a rate of risk of future liver-related events that is similar to patients with a FIB-4 1.3 [81].”
InfluentialCusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204 · cited 1×
“Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been widely used for the treatment of T2DM and cardiovascular disease, with some evidence of benefit for MAFLD [209, 210].”
Artificial Intelligence Applications in Health Care Practice: Scoping Review
Sharma, M., Savage, C., Nair, M., Larsson, I., Svedberg, P., & Nygren, J. M. (2022) · Journal of Medical Internet Research · doi:10.2196/40238 · Cited by 198 · cited 1×
“This ranges from predictive analytics through data mining of various large datasets, to management systems to robotic surgery and personalized medicine [412].”
Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.045 · Cited by 197
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191
Self-citationRisks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts
Åberg, F., Puukka, P., Salomaa, V., Männistö, S., Lundqvist, A., Valsta, L., Perola, M., Färkkilä, M., & Jula, A. (2020) · Hepatology · doi:10.1002/hep.30864 · Cited by 176 · cited 1×
“A study involving 8,345 individuals with hepatic steatosis with a mean follow-up of 11.1 years found that even a modest alcohol intake of 10–19 g/day doubled the risk for advanced liver disease [409].”
InfluentialRauschecker, A. M., Rudie, J. D., Xie, L., Wang, J., Duong, M. T., Botzolakis, E. J., Kovalovich, A. M., Egan, J., Cook, T. C., Bryan, R. N., et al. (2020) · Radiology · doi:10.1148/radiol.2020190283 · Cited by 148
Kawaguchi, T., Charlton, M., Kawaguchi, A., Yamamura, S., Nakano, D., Tsutsumi, T., Zafer, M., & Torimura, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723751 · Cited by 122 · cited 1×
“A Mediterranean-style diet is associated with a reduced risk of T2DM, CVD, liver fat, and fibrosis in patients with MAFLD [160–162].”
Self-citationKeating, S. E., Sabag, A., Hallsworth, K., Hickman, I. J., Macdonald, G. A., Stine, J. G., George, J., & Johnson, N. A. (2023) · Sports Medicine · doi:10.1007/s40279-023-01918-w · Cited by 119 · cited 6×
“There are no evidence-supported recommendations regarding the intensity, frequency, number of sets and repetitions of resistance exercise required for hepatic benefit [170].”
InfluentialSelf-citationCholankeril, G., Kramer, J. R., Chu, J., Yu, X., Balakrishnan, M., Li, L., El-Serag, H. B., & Kanwal, F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.035 · Cited by 119
Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study
Ayada, I., van Kleef, L. A., Zhang, H., Liu, K., Li, P., Abozaid, Y. J., Lavrijsen, M., Janssen, H. L. A., van der Laan, L. J. W., Ghanbari, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2022.104392 · Cited by 117 · cited 1×
“[234] Statins have shown potential benefits on liver function tests in patients with MAFLD [235, 236], but their efficacy on steatosis or fibrosis is uncertain.”
Hayat, U., Siddiqui, A. A., Okut, H., Afroz, S., Tasleem, S., & Haris, A. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2020.08.071 · Cited by 105
Dietary patterns and risk of hepatocellular carcinoma among U.S. Men and women
Ma, Y., Yang, W., Simon, T. G., Smith‐Warner, S. A., Fung, T. T., Sui, J., Chong, D., VoPham, T., Meyerhardt, J. A., Wen, D., et al. (2019) · Hepatology · doi:10.1002/hep.30362 · Cited by 103
AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review
Patton, H., Heimbach, J., & McCullough, A. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.034 · Cited by 97 · cited 1×
“Nonetheless, bariatric surgery (usually sleeve gastrectomy) can be considered in carefully selected patients with compensated cirrhosis, ideally in high-volume centres and taking into account liver status, clinically significant portal hypertension, comorbidities and surgical factors [357, 358].”
Stine, J. G., DiJoseph, K., Pattison, Z., Harrington, A., Chinchilli, V. M., Schmitz, K. H., & Loomba, R. (2023) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002098 · Cited by 94
Stine, J. G., Long, M. T., Corey, K. E., Sallis, R. E., Allen, A. M., Armstrong, M. J., Conroy, D. E., Cuthbertson, D. J., Duarte-Rojo, A., Hallsworth, K., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000108 · Cited by 89
Self-citationSabag, A., Barr, L., Armour, M., Armstrong, A., Baker, C. J., Twigg, S. M., Chang, D., Hackett, D. A., Keating, S. E., George, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab795 · Cited by 88 · cited 1×
“…for hepatic steatosis [180–182], emerging evidence demonstrates that high-intensity interval training (HIIT) involving one or more bursts of high-intensity exercise interspersed with lower-intensity recovery periods is equally effective under the supervision of an exercise professional [181] [183].”
Self-citationJirapinyo, P., McCarty, T. R., Dolan, R. D., Shah, R., & Thompson, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.017 · Cited by 86
Tsai, P.-C., Kuo, H.-T., Hung, C.-H., Tseng, K.-C., Lai, H.-C., Peng, C.-Y., Wang, J.-H., Chen, J.-J., Lee, P.-L., Chien, R.-N., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.019 · Cited by 82 · cited 2×
“DAA therapy for HCV eradication and lifestyle modification for weight reduction remain the cornerstone of management in patients with combined CHC and MAFLD [403].”
Self-citationDel Bo’, C., Perna, S., Allehdan, S., Rafique, A., Saad, S., AlGhareeb, F., Rondanelli, M., Tayyem, R. F., Marino, M., Martini, D., et al. (2023) · Nutrients · doi:10.3390/nu15102250 · Cited by 80
Rational HCC screening approaches for patients with NAFLD
Singal, A. G., & El-Serag, H. B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.028 · Cited by 80
Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis
Zhou, H., Luo, P., Li, P., wang, G., Yi, X., Fu, Z., Sun, X., Cui, B., Zhu, L., & Zhu, S. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06011-1 · Cited by 79
Interaction between sarcopenia and nonalcoholic fatty liver disease
Joo, S. K., & Kim, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0358 · Cited by 78
Self-citationWong, Y. J., Nguyen, V. H., Yang, H.-I., Li, J., Le, M. H., Wu, W.-J., Han, N. X., Fong, K. Y., Chen, E., Wong, C., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0004 · Cited by 77 · cited 1×
“However, MAFLD is associated with a significantly lower risk of HCC and a higher chance of hepatitis B surface antigen (HBsAg) seroclearance than those without MAFLD [378, 379].”
Self-citationThe Health Benefits of Resistance Exercise: Beyond Hypertrophy and Big Weights
Abou Sawan, S., Nunes, E. A., Lim, C., McKendry, J., & Phillips, S. M. (2023) · Exercise, Sport and Movement · doi:10.1249/esm.0000000000000001 · Cited by 76
Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01861-9 · Cited by 75
Macrophages in metabolic associated fatty liver disease
Alharthi, J., Latchoumanin, O., George, J., & Eslam, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1861 · Cited by 65 · cited 1×
“Recent studies indicate that gut microbiota and its metabolites play a critical role in the onset of MAFLD [44, 45].”
Self-citationChun, H. S., Lee, M., Lee, H. A., Oh, S. Y., Baek, H. J., Moon, J. W., Kim, Y. J., Lee, J., Kim, H., Kim, H. Y., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.043 · Cited by 60
Self-citationMak, L.-Y., Hui, R. W.-H., Fung, J., Liu, F., Wong, D. K.-H., Li, B., Cheung, K.-S., Yuen, M.-F., & Seto, W.-K. (2021) · Hepatology International · doi:10.1007/s12072-021-10218-2 · Cited by 58 · cited 1×
“Several studies report that hepatic steatosis confers a lower risk of HCC among untreated CHB patients [286, 380, 381].”
Self-citationCassinotto, C., Boursier, J., Paisant, A., Guiu, B., Irles‐Depe, M., Canivet, C., Aube, C., & de Ledinghen, V. (2021) · Hepatology · doi:10.1002/hep.31655 · Cited by 55 · cited 2×
“[82].”
Zhang, X., Yip, T. C.-F., Wong, G. L.-H., Leow, W.-X., Liang, L. Y., Lim, L.-L., Li, G., Ibrahim, L., Lin, H., Lai, J. C. T., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330269 · Cited by 55 · cited 1×
“[91] New combinations of novel NIT’s are likely to be more accurate and can result in fewer inappropriate referrals, however, they will need to be of low cost and easily available to enable wide-spread implementation.”
Self-citationEslam, M., Wong, G. L.-H., Hashem, A. M., Chan, H. L.-Y., Nielsen, M. J., Leeming, D. J., Chan, A. W.-H., Chen, Y., Duffin, K. L., Karsdal, M., et al. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001059 · Cited by 53
Self-citationLange, M., Nadkarni, D., Martin, L., Newberry, C., Kumar, S., & Kushner, T. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000212 · Cited by 49
Coffee consumption is associated with lower liver stiffness: a nationally representative study
Niezen, S., Mehta, M., Jiang, Z. G., & Tapper, E. B. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.042 · Cited by 47
Harris, S. J., Smith, N., Hummer, B., Schreibman, I. R., Faust, A. J., Geyer, N. R., Chinchilli, V. M., Sciamanna, C., Loomba, R., & Stine, J. G. (2024) · Liver International · doi:10.1111/liv.15769 · Cited by 31
Verna, E. C., Phipps, M. M., Halazun, K. J., Markovic, D., Florman, S. S., Haydel, B. M., Ruiz, R., Klintmalm, G., Lee, D. D., Taner, B., et al. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000007 · Cited by 16
Lee, S.-Y., Lai, H., Chua, Y. J., Wang, M. X., & Lee, G.-H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.880749 · Cited by 14
Metadata
- Authors
- Eslam, M., Fan, J.-G., Yu, M.-L., Wong, V. W.-S., Cua, I. H., Liu, C.-J., Tanwandee, T., Gani, R., Seto, W.-K., Alam, S., Young, D. Y., Hamid, S., Zheng, M.-H., Kawaguchi, T., Chan, W.-K., Payawal, D., Tan, S.-S., Goh, G. B.-B., Strasser, S. I., Viet, H. D., Kao, J.-H., Kim, W., Kim, S. U., Keating, S. E., Yilmaz, Y., Kamani, L., Wang, C.-C., Fouad, Y., Abbas, Z., Treeprasertsuk, S., Thanapirom, K., Al Mahtab, M., Lkhagvaa, U., Baatarkhuu, O., Choudhury, A. K., Stedman, C. A. M., Chowdhury, A., Dokmeci, A. K., Wang, F.-S., Lin, H.-C., Huang, J.-F., Howell, J., Jia, J., Alboraie, M., Roberts, S. K., Yoneda, M., Ghazinian, H., Mirijanyan, A., Nan, Y., Lesmana, C. R. A., Adams, L. A., Shiha, G., Kumar, M., Örmeci, N., Wei, L., Lau, G., Omata, M., Sarin, S. K., & George, J.
- Venue
- Hepatology International
- Published
- 2025-02-27
- Volume
- 19
- Issue
- 2
- Pages
- 261-301
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- OpenAlex
- W4408013956
- Cited by
- 170
- References
- 101
- FWCI
- 103.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.